$55.59
0.63%
Nasdaq, Nov 16, 11:19 am EST. Market open.
ISIN
US55287L1017
Symbol
MBX

Mbx Biosciences Inc Stock price

$55.94
+6.94 14.16% 1M
+18.44 49.17% 6M
+24.40 77.36% YTD
+31.87 132.41% 1Y
+39.94 249.63% 3Y
+39.94 249.63% 5Y
+39.94 249.63% 10Y
+39.94 249.63% 20Y
Nasdaq, Closing price Fri, Nov 13 2026
+1.43 2.62%
ISIN
US55287L1017
Symbol
MBX
Industry

AI Insights on Mbx Biosciences Inc Insights AI Insights on Mbx Biosciences Inc

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is Mbx Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$2.8b
Enterprise Value
$2.4b
Net debt
positive
Cash
$418.6m
Shares outstanding
48.0m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
negative | negative
P/B
6.8
Financial Health
Equity Ratio
95.9%
Return on Equity
-23.6%
ROCE
-28.6%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$16.5m | -
SBC as % of FCF
-
SBC Growth 1Y
155.0%
Share Count Growth 1Y
42.8%
Shareholder Yield
-42.8%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-117.7m
EBIT
$-117.9m
Net Income
$-104.3m
Free Cash Flow | ex SBC
$-85.2m | $-101.7m
Growth
Revenue | estimate
- | -
EBITDA
-36.4%
EBIT
-36.2%
Net Income
-35.4%
Free Cash Flow
-18.8%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-2.2
FCF per Share
$-1.8
Short interest
11.9%
Employees
63
Rev per Employee
$0.0

Mbx Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Mbx Biosciences Inc forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a Mbx Biosciences Inc forecast:

Buy
93%
Hold
7%

Mbx Biosciences Inc Events

Past Events
NOV
9
Q3 2026 Earnings Call
7 days ago
SEP
16
Morgan Stanley 24th Annual Global Healthcare Conference
2 months ago
JUN
12
Special Call - MBX Biosciences, Inc.
5 months ago
MAY
11
Special Call - MBX Biosciences, Inc.
6 months ago
JAN
13
44th Annual J.P. Morgan Healthcare Conference
10 months ago

Financial data from Mbx Biosciences Inc

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 29 29
104% 104%
-
- Research and Development Expense 88 88
23% 23%
-
-118 -118
36% 36%
-
- Depreciation and Amortization 0.25 0.25
7% 7%
-
EBIT (Operating Income) EBIT -118 -118
36% 36%
-
Net Profit -104 -104
35% 35%
-

In millions USD.

Don't miss a Thing! We will send you all news about Mbx Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mbx Biosciences Inc Stock News

Neutral
GlobeNewsWire
●
7 days ago
Enrollment in pivotal Phase 3 oPTimize trial of once-weekly canvuparatide underway 12-week MAD (Part C, Cohort 1) data for MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity designed for once-monthly dosing, on track for Q4 2026 Preclinical data for MBX 6180, a GLP-1/GIP/GCG triple agonist prodrug with potential for once-monthly dosing, accepted for presentation at ObesityWeek 2026 $481.6 mil...
Neutral
GlobeNewsWire
●
2 months ago
CARMEL, Ind. and BURLINGTON, Mass.
Neutral
GlobeNewsWire
●
3 months ago
Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable one-year clinical benefit
More Mbx Biosciences Inc News

Company Profile

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. The company is headquartered in Carmel, Indiana and currently employs 63 full-time employees. The company went IPO on 2024-09-13. The firm is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies that are designed to overcome key limitations of current peptide therapies. Its product candidates and programs include MBX 2109, MBX 1416 and Obesity portfolio. MBX 2109 is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. MBX 1416 is designed to be a long-acting glucagon-like peptide-1 (GLP-1), receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX 4291 is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, receptor co-agonist prodrug.

Head office United States
CEO Mr. Hawryluk
Employees 63
Website mbxbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today